Compare change is SVC and SMA flow due to GIP antagonist GIP(3-30)NH2

Phase 2

HeartSciences Inc. (HSCSW)

00%

What is LOA?

Phase 2

Development Phase

Upcoming Catalysts

Historical Events

Regulatory Approvals

Upcoming Catalysts

What are catalysts?

Q2 '27

HSCSWPhase 2

Compare change is SVC and SMA flow due to GIP antagonist GIP(3-30)NH2 Phase 2 Est. Readout

Compare change is SVC and SMA flow due to GIP antagonist GIP(3-30)NH2• Postural Tachycardia Syndrome (POTS)50

Q2 2027~QConfirmed

CT.gov

00%

Competitive Landscape

0 competitors in Postural Tachycardia Syndrome (POTS)

View Full Landscape

Drug Information

Target Indication

Postural Tachycardia Syndrome (POTS)

Clinical Trial

NCT05375968

Last updated: 9/10/2026

Patent & Exclusivity

No patent data available. Pre-approval drugs may not have Orange Book listings.

Source: FDA Orange Book

Drug Science

Mechanism of action & safety profile

Developer

HSCSW

HeartSciences Inc.

Biotechnology•North America•NASDAQ

Related Pipeline

Sinerem administrationPhase 3

Aortic Aneurysm

Fresh frozen plasma transfusionPhase 3

Blood Coagulation Disorders

Mono-Therapy with SildenafilPhase 3

Pediatric Pulmonary Hypertension

NedocromilPhase 3

Asthma

Bupropion HCl ERPhase 3

Acute Coronary Syndrome

View full pipeline

Get Catalyst Alerts

Receive weekly digests of upcoming catalysts